INVA — Innoviva, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1080014 ·
Last close
$18.30
Market Cap
$1.30B
52W High
$25.15
52W Low
$18.28
ADV30
801,024
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 106,120,000 84,382,000 42,153,000 -73,888,000 1,537,926,000 581,394,000 400,408,000
Jun 2026 119,591,000 90,616,000 50,855,000 -83,420,000 1,702,727,000 570,388,000 469,465,000
Mar 2026 97,994,000 82,387,000 38,154,000 186,595,000 1,836,587,000 603,085,000 494,932,000
Dec 2025 114,613,000 101,944,000 38,988,000 164,153,000 1,635,165,000 550,941,000 462,324,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$183,465,000
Investing CF
$-49,000
Financing CF
$-78,535,000
CapEx
$-955,000
Dividends Paid
—
Buybacks
$-82,257,000
EPS Diluted TTM
$1.99
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$298,655,000
Inventory
$42,838,000
Receivables
$102,130,000
ST Investments
$8,667,000
EBIT TTM
$243,659,000
Pretax Income TTM
$223,969,000
Interest Exp TTM
$19,690,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$438,318,016
EBITDA
$199,807,008
Free Cash Flow
$121,162,376
Enterprise Value
$1,098,630,272
Total Cash
$590,060,992
Total Debt
$331,035,008
Shares Out
71,081,477
Trailing EPS
$2.35
Book Value
$15.90
ROE
18.0%
ROA
7.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 411,328,000 163,745,000 271,165,000 1,635,165,000 462,324,000 1,172,841,000 196,930,000
Dec 2024 358,711,000 166,867,000 23,392,000 1,301,060,000 609,901,000 691,159,000 188,690,000
Dec 2023 310,463,000 113,885,000 179,722,000 1,243,507,000 568,552,000 674,955,000 141,064,000
Dec 2022 331,339,000 206,995,000 213,921,000 1,231,497,000 665,709,000 565,788,000 201,726,000

TTM Snapshot

Revenues TTM
$439,998,000
NetIncome TTM
$357,236,000
OpCashFlow TTM
—
Assets (Latest)
$1,702,727,000
Forward EPS
$2.21

Max Pain — expiry 2026-12-18

max pain strike: $22.50 · spot: $18.40 · call oi: 1,008 · put oi: 244
Expected Move to 2026-12-18: ±$3.95 (21.47%) — implied range $14.45 – $22.35 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GPCR Structure Therapeutics Inc. $1.30B $18.17 —
LBRX LB PHARMACEUTICALS INC $1.30B $40.30 —
MNKD MANNKIND CORP $1.31B $4.07 —
MLYS Mineralys Therapeutics, Inc. $1.28B $14.48 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —

News headlines (Yahoo Finance, 1h cache)

Is Quarterly Loss Altering The Investment Case For Innoviva Stock (INVA)?
2026-11-16 23:23 · Yahoo
Is Innoviva (INVA) Stock Undervalued Right Now?
2026-11-10 13:40 · Yahoo
INVA or MRK: Which Is the Better Value Stock Right Now?
2026-11-09 15:40 · Yahoo
Innoviva (INVA) Tops Q3 Earnings Estimates
2026-11-04 23:45 · Yahoo
Innoviva: Q3 Earnings Snapshot
2026-11-04 23:05 · Yahoo
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
2026-10-19 12:00 · Yahoo
Do Options Traders Know Something About Innoviva Stock We Don't?
2026-10-12 14:11 · Yahoo
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
2026-10-08 19:19 · Yahoo
INVA vs. MRK: Which Stock Is the Better Value Option?
2026-10-08 14:40 · Yahoo
Should Value Investors Buy Innoviva (INVA) Stock?
2026-10-08 12:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.